Clinical trial
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
NCT00790699
Study timeline
Study start (unknown)2009-08-01Date precision: month
Registry last updated2020-10-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 1 Diabetesunresolved
Type 2 Diabetesunresolved
Interventions
I-PORTDEVICE
standard injectionsOTHER
Sponsors & collaborators
Texas Diabetes & Endocrinology, P.A.lead sponsor
Amylin Pharmaceuticals, LLC.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00790699 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.